The experimental therapeutic (TE) axis of the FRQS network is an entity created by the Center of Experimental Therapy for Cancer of Montreal (CTECM) located at the Jewish General Hospital and is comprised of Quebec researchers dedicated to applied cancer research. Their mission is to develop new therapeutic paradigms for the benefit of the entire community. The TE axis plays a key coordinating role, especially between the basic, translational and clinical research environment.
The axes focuses on several themes that include:
- Research focused on biomarkers, especially biopsies, to integrate them into a personalized medicine approach.
- Integration of new treatments for the care of cancer patients by supporting molecular modeling and development of new drugs.
- Development of new approaches to precision medicine, integrating new models of therapeutic trials in personalized medicine as well as developing studies guided by the molecular basis of cancer in order to match the patient with the best targeted therapies.
The CTECM collaborates with many leading edge companies in biotechnology and pharmacology, including the important cancer centers in Canada. Moreover, a bridge with the bio-pharmaceutical industry is an integral part of the development plan for the experimental therapeutic axis for the purpose of rapidly developing new cancer treatments.